Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.79M
Average 1.74M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +29.5% | +31.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +29.5% over three years. Forward estimates point to Revenue at +31.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Revolution Medicines, Inc. NASDAQ:RVMD | $37.26B | $172.29 | Not rated | -23.3 | +126.05% |
Kymera Therapeutics, Inc. NASDAQ:KYMR | $10.89B | $127.57 | Not rated | -28.3 | +86.87% |
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | $25.50 | Not rated | -38.9 | +164.05% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -48.77% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | +2.04% |
Kura Oncology, Inc. NASDAQ:KURA | $713.90M | $7.77 | Not rated | -2.9 | -35.16% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | -1.00% |
Continue the stock analysis
Jump to another research area for this company.